TABLE 1.
Patient background
| n = 132 | |
|---|---|
| Age, year | 71 (36‐86) |
| Sex | |
| Male | 66 (50) |
| Female | 66 (50) |
| ASA | |
| 1 | 24 (18.2) |
| 2 | 107 (81.1) |
| 3 | 1 (0.8) |
| Performance status | |
| 0 | 105 (79.5) |
| 1 | 26 (19.7) |
| 2 | 1 (0.8) |
| Dominant location of tumor, n | |
| Head | 81 (61.4) |
| Body | 32 (24.2) |
| Tail | 19 (14.4) |
| Tumor size, mm | 23 (10‐63) |
| Clinical T stage (UICC 8th) | |
| T1b | 2 (1.5) |
| T1c | 44 (33.3) |
| T2 | 78 (59.1) |
| T3 | 8 (6.1) |
| Clinical T stage (UICC 7th) | |
| T1 | 15 (11.4) |
| T2 | 9 (6.8) |
| T3 | 108 (81.8) |
| Histological diagnosis | |
| Confirmed | 122 (92.4) |
| CA19‐9 levels, U/mL | 83.1 (<0.4‐11700) |
| DUPAN‐2 levels, U/mL a | 110 (<25‐>1600) |
| Type of radiation | |
| IMRT | 22 (16.7) |
Note: Expressed as median (range) or number (percentage).
Abbreviations: ASA, American Society of Anesthesiologists; IMRT, intensity‐modulated radiotherapy; UICC, Union for International Cancer Control.
a
Data of five patients are missing.